Ovarian Cancer Treatment with Intensive Chemotherapy
Author Information
Author(s): A Weaver, E Wrigley, A Watson, J Chang, CD Collins, B Jenkins, C Gill, R Pettengell, TM Dexter, NG Testa, D Crowther
Primary Institution: Christie Hospital, Manchester
Hypothesis
Can dose-intensive chemotherapy supported by peripheral blood progenitor cells improve outcomes in ovarian cancer patients?
Conclusion
The study found that dose-intensive chemotherapy can be safely administered with low toxicity, achieving a 70% overall response rate in ovarian cancer patients.
Supporting Evidence
- Five patients achieved complete remission, and five achieved partial remission, resulting in a 70% overall response rate.
- Patients treated with the 3-week regimen tolerated the treatment well, with 83% receiving the planned dose intensity.
- Thrombocytopenia was the main reason for treatment delays in the 2-week regimen.
Takeaway
Doctors tested a stronger chemotherapy for ovarian cancer and found it worked well for most patients without making them too sick.
Methodology
Patients received filgrastim to mobilize progenitor cells, followed by chemotherapy with cyclophosphamide and carboplatin, with apheresis to collect progenitor cells.
Potential Biases
Potential bias due to the small number of patients and the lack of a control group.
Limitations
The small sample size and the fact that not all patients completed the treatment as planned due to side effects.
Participant Demographics
Patients aged 16 to 65 with histologically proven epithelial ovarian cancer, FIGO stage Ic-IV.
Statistical Information
P-Value
0.03
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website